The cause for clinical resistance has not yet been identified and there is little evidence for FLT3 mutations that are analogous to the BCR-ABL gate-keeper mutations in CML, observed in response to imatinib and related compounds. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.